Sign in

CIK 0001840229 · <br>Emerging growth company

MiNK Therapeutics, Inc.

Sign in to watch
Ticker
INKT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
212-994-8250
Business address
149 FIFTH AVENUE, SUITE 500, NEW YORK, NY, 10010
Former names
AgenTus Therapeutics, Inc., AgenTus Therapeutics, Inc.
  1. 4 Grant or award Director acquired 17,188 shares (grant or award)
  2. 4 Grant or award Director acquired 14,424 shares (grant or award)
  3. 4 Grant or award Director acquired 14,784 shares (grant or award)
  4. 10-Q Report Quarterly Report
  5. 8-K Event Results of operations
  6. 8-K Event Executive or director change
  7. 4 Open-market buy 10% owner bought 22,975 shares at an average $1.10 ($25,270)
  8. 4 Other disposition Chief Executive Officer disposed of 695,750 shares (other)
  9. 4 Open-market buy 10% owner bought 15,001 shares at $1.09 ($16,380)
  10. 4 Shares withheld for taxes Chief Executive Officer gave up 148,550 shares (to pay taxes)
  11. 4 Option exercise Chief Executive Officer acquired 695,750 shares (option exercise)
  12. 4 Grant or award Director acquired 10,531 shares (grant or award)
  13. 4 Grant or award Director acquired 12,244 shares (grant or award)
  14. 4 Grant or award Director acquired 9,846 shares (grant or award)
  15. 4 Grant or award Director acquired 12,158 shares (grant or award)
  16. 4 Grant or award Director acquired 9,590 shares (grant or award)
  17. 4 Open-market buy 10% owner bought 29,678 shares at $1.52 ($45,016)
  18. 4 Open-market buy 10% owner bought 183,052 shares at an average $1.54 ($281,478)
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. 8-K Event Results of operations

Page 8 of 14 · 267 filings